3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Hepatocellular
59
Cholangiocarcinoma
19
Carcinoma, Renal Cell
16
Biliary Tract Neoplasms
11
Stomach Neoplasms
9
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
7
Melanoma
6
Uterine Cervical Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Neuroendocrine Tumors
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Vulvar Neoplasms
2
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Thymoma
2
Solid Tumors
2
Interventions
lenvatinib
1
camrelizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Triple Negative Breast Cancer
×
lenvatinib
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled